Nephron-sparing surgery for renal cell carcinoma.
Nephron-sparing surgery (NSS) provides effective curative therapy for patients with localized renal cell carcinoma. In patients with imperative indications, it represents an alternative to renal replacement therapy. For selected patients with systemic comorbidities that threaten global renal function, NSS preserves unaffected nephrons with excellent cancer-specific survival. Elective partial nephrectomy for patients with a small (< or = 4 cm), unifocal tumor and a normal contralateral kidney is associated with a low risk (0%-3%) of local recurrence and cancer-specific survival rates of 90%-100%. Comparisons between radical and partial nephrectomy demonstrate equivalent cancer control over five years. Minimally invasive techniques of NSS are feasible but await improved technologies and long-term outcome data before they become fully acceptable treatment options.
Novick
Andrew C
AC
The Cleveland Clinic Foundation, Urological Institute, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. novicka@ccf.org
D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D007677:Kidney Function Tests; D007680:Kidney Neoplasms / Q000401:mortality / Q000601:surgery*; D016030:Kidney Transplantation; D009392:Nephrectomy / Q000379:methods*; D009399:Nephrons / Q000601:surgery*; D015996:Survival Rate